citalopram has been researched along with Cardiovascular Diseases in 13 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The DECARD (DEpression in patients with Coronary ARtery Disease) trial assessed the prophylactic effect of escitalopram on depression after ACS." | 9.16 | Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome: results from the DEpression in patients with Coronary ARtery Disease (DECARD) trial. ( Birket-Smith, M; Hanash, JA; Hansen, BH; Hansen, JF; Nielsen, OW; Rasmussen, A, 2012) |
| "The DECARD (DEpression in patients with Coronary ARtery Disease) trial assessed the prophylactic effect of escitalopram on depression after ACS." | 5.16 | Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome: results from the DEpression in patients with Coronary ARtery Disease (DECARD) trial. ( Birket-Smith, M; Hanash, JA; Hansen, BH; Hansen, JF; Nielsen, OW; Rasmussen, A, 2012) |
| " To compare the effects of antidepressant drugs, the electrocardiogram (ECG), vectorcardiogram (VCG), and body surface maps (BSM) were recorded in psychiatric patients without cardiovascular diseases treated by a) TCA amitriptyline or dosulepin (daily dose 50-200 mg, 22 patients), b) lithium (serum level 0." | 3.70 | Antidepressant drugs and heart electrical field. ( Hamplová, J; Horácek, BM; Kittnar, O; Paclt, I; Slavícek, J; Trefný, Z, 1998) |
| "We investigated whether treating depression in older participants impacted on arterial stiffness, a known cardiovascular disease risk factor and a clinical marker of arterial aging." | 2.78 | Depression treatment selectively modifies arterial stiffness in older participants. ( Assisi, AP; Fedullo, F; Gianni, W; Modestino, A; Scuteri, A, 2013) |
| "Escitalopram (n=3298) was administered at doses between 5 and 20mg/day." | 1.39 | The cardiovascular safety profile of escitalopram. ( Kennedy, SH; Larsen, KG; Reines, E; Thase, ME, 2013) |
| " The aim of this study was to investigate the toxic effects and toxicokinetic parameters of citalopram in an overdose as a single drug and in combination with other drugs." | 1.35 | Clinical toxicology of citalopram after acute intoxication with the sole drug or in combination with other drugs: overview of 26 cases. ( Caminada, K; Hunfeld, NG; Jimmink, A; Touw, DJ, 2008) |
| "The aim of the present study was to compare cardiovascular and/or cardiotoxic effects of eight anti-depressants (imipramine, chlorimipramine, amitriptyline, nortriptyline , doxepin, maprotiline, mianserin and citalopram) in anaesthetized cats after oral dosing and in conscious rabbits after intravenous infusion." | 1.27 | Comparative animal studies on cardiovascular toxicity of tri- and tetracyclic antidepressants and citalopram; relation to drug plasma levels. ( Boeck, V; Fredricson Overø, K; Jørgensen, A, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, WT | 1 |
| Tsai, CT | 1 |
| Chou, YC | 1 |
| Ku, PM | 1 |
| Chen, YC | 1 |
| You, SL | 1 |
| Hung, CF | 1 |
| Sun, CA | 1 |
| Gerlach, LB | 1 |
| Kim, HM | 1 |
| Yosef, M | 1 |
| Kales, HC | 1 |
| Henry, J | 1 |
| Zivin, K | 1 |
| Guo, S | 1 |
| Chen, L | 1 |
| Cheng, S | 1 |
| Xu, H | 1 |
| Thase, ME | 1 |
| Larsen, KG | 1 |
| Reines, E | 1 |
| Kennedy, SH | 1 |
| Jimmink, A | 1 |
| Caminada, K | 1 |
| Hunfeld, NG | 1 |
| Touw, DJ | 1 |
| Kamarck, TW | 1 |
| Haskett, RF | 1 |
| Muldoon, M | 1 |
| Flory, JD | 1 |
| Anderson, B | 1 |
| Bies, R | 1 |
| Pollock, B | 1 |
| Manuck, SB | 1 |
| Jiang, W | 1 |
| Velazquez, EJ | 1 |
| Samad, Z | 1 |
| Kuchibhatla, M | 1 |
| Martsberger, C | 1 |
| Rogers, J | 1 |
| Williams, R | 1 |
| Kuhn, C | 1 |
| Ortel, TL | 1 |
| Becker, RC | 1 |
| Pristera, N | 1 |
| Krishnan, R | 1 |
| O'Connor, CM | 1 |
| Hanash, JA | 1 |
| Hansen, BH | 1 |
| Hansen, JF | 1 |
| Nielsen, OW | 1 |
| Rasmussen, A | 1 |
| Birket-Smith, M | 1 |
| Thombs, BD | 1 |
| Scuteri, A | 1 |
| Modestino, A | 1 |
| Fedullo, F | 1 |
| Assisi, AP | 1 |
| Gianni, W | 1 |
| de Jonge, P | 1 |
| Honig, A | 1 |
| van Melle, JP | 1 |
| Schene, AH | 1 |
| Kuyper, AM | 1 |
| Tulner, D | 1 |
| Schins, A | 1 |
| Ormel, J | 1 |
| Boeck, V | 1 |
| Jørgensen, A | 1 |
| Fredricson Overø, K | 1 |
| Slavícek, J | 1 |
| Paclt, I | 1 |
| Hamplová, J | 1 |
| Kittnar, O | 1 |
| Trefný, Z | 1 |
| Horácek, BM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT Trial)[NCT00574847] | Phase 4 | 127 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: week 6
| Intervention | fmol/mg (Mean) |
|---|---|
| Escitalopram | 139.7 |
| Placebo | 160.4 |
The Beck Depression Inventory II (BDI-II) is a 21 question, self-administered measure of depressive symptoms. Score range, 0 to 63 (higher score=greater severity of depressive symptoms). End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 week
| Intervention | units on a scale (Mean) |
|---|---|
| Escitalopram | 7.4 |
| Placebo | 7.0 |
hostile affect, 0 to 5 (higher score=greater levels of hostile affect). End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Escitalopram | 1.6 |
| Placebo | 1.8 |
Score ranges: hostility, 0 to 27 (higher score=greater levels of hostility)/ End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Escitalopram | 9.9 |
| Placebo | 10.3 |
End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 week
| Intervention | percentage of change (Number) |
|---|---|
| Escitalopram | 45.8 |
| Placebo | 52.5 |
"A standard 12-lead Electrocardiograph (ECG) will be recorded at 1-minute intervals during the last 3 minutes of each rest period, the 3 minutes of the mental stress testing, and during exercise testing. Heart rate will be determined from the ECGs.~Mental Stress Induced Change in heart rate will be calculated by taking the mean of the mental stress heart rate measurements minus the resting heart rate measurements. End point values adjusted for baseline values age and sex." (NCT00574847)
Timeframe: baseline, 6 weeks
| Intervention | beats/minute (Mean) |
|---|---|
| Escitalopram | 6.34 |
| Placebo | 9.1 |
Blood pressure will be measured the last 3 minutes of the 20 minute calibration period (resting), every minute during the 3 minutes mental stress testing, the last 3 minutes of the 6 minute rest periods between mental stress testing, and every minute during and after the physical stress testing with an automatic oscillometric blood pressure monitor (Quinton Electronics). Mental Stress Induced Change of Diastolic Blood Pressure will be calculated by taking the mean of the mental stress Diastolic blood pressure measurements minus the resting Diastolic blood pressure. End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: Baseline, week 6
| Intervention | mm Hg (Mean) |
|---|---|
| Escitalopram | 11.4 |
| Placebo | 12.2 |
Blood pressure will be measured the last 3 minutes of the 20 minute calibration period (resting), every minute during the 3 minutes mental stress testing, the last 3 minutes of the 6 minute rest periods between mental stress testing, and every minute during and after the physical stress testing with an automatic oscillometric blood pressure monitor (Quinton Electronics). Mental Stress Induced Change of Systolic Blood Pressure will be calculated by taking the mean of the mental stress systolic blood pressure measurements minus the resting Systolic blood pressure. End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: Baseline, week 6
| Intervention | mm Hg (Mean) |
|---|---|
| Escitalopram | 19.3 |
| Placebo | 23.6 |
Score range, 10 to 50 (higher score = greater levels of perceived stress). End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Escitalopram | 21.4 |
| Placebo | 21.8 |
(NCT00574847)
Timeframe: Baseline to week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Escitalopram | 71.9 |
| Placebo | 44.4 |
MSIMI is defined by the following: compared to rest, 1) any development of new abnormal wall motion; 2) reduction of LVEF 8% and/or; 3) deviation (depression or elevation) of ST-segment of ECG in 2 or more leads lasting for 3 consecutive beats, occurring during at least one of the 3 mental stress tasks. (NCT00574847)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Escitalopram | 34.2 |
| Placebo | 17.5 |
MSIMI is defined by the following: compared to rest, 1) any development of new abnormal wall motion; 2) reduction of LVEF 8% and/or; 3) deviation (depression or elevation) of ST-segment of ECG in 2 or more leads lasting for 3 consecutive beats, occurring during at least one of the 3 mental stress tasks. (NCT00574847)
Timeframe: week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Escitalopram | 66.1 |
| Placebo | 83.9 |
End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks
| Intervention | nM (Mean) |
|---|---|
| Escitalopram | 4202.4 |
| Placebo | 210.1 |
STAI measures anxiety. The questionnaire asks the patients how they feel and allows them to respond on a frequency scale that ranges from 1(not at all) to 4(almost always/very much so). Scores range from 20-80 and the higher the score the greater the anxiety level. This applies to both the Trait and State scales. End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Trait | State | |
| Escitalopram | 31.2 | 27.9 |
| Placebo | 32.0 | 29.5 |
1 review available for citalopram and Cardiovascular Diseases
| Article | Year |
|---|---|
Comparative cardiovascular safety of selective serotonin reuptake inhibitors (SSRIs) among Chinese senile depression patients: A network meta-analysis of randomized controlled trials.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Asian People; Cardiovascular Diseases; China; Citalo | 2019 |
5 trials available for citalopram and Cardiovascular Diseases
| Article | Year |
|---|---|
Citalopram intervention for hostility: results of a randomized clinical trial.
Topics: Adult; Aggression; Cardiovascular Diseases; Citalopram; Drug Administration Schedule; Female; Hostil | 2009 |
Responses of mental stress-induced myocardial ischemia to escitalopram treatment: background, design, and method for the Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment trial.
Topics: Adult; Cardiovascular Diseases; Citalopram; Depressive Disorder; Exercise Test; Humans; Myocardial I | 2012 |
Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome: results from the DEpression in patients with Coronary ARtery Disease (DECARD) trial.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Citalopram; Depression; Double-Blind Method; | 2012 |
Depression treatment selectively modifies arterial stiffness in older participants.
Topics: Aged; Aging; Antidepressive Agents; Antidepressive Agents, Second-Generation; Blood Pressure; Cardio | 2013 |
Nonresponse to treatment for depression following myocardial infarction: association with subsequent cardiac events.
Topics: Antidepressive Agents; Cardiovascular Diseases; Cause of Death; Citalopram; Comorbidity; Depressive | 2007 |
7 other studies available for citalopram and Cardiovascular Diseases
| Article | Year |
|---|---|
Cardiovascular Outcomes Associated With Clinical Use of Citalopram and Omeprazole: A Nationwide Population-Based Cohort Study.
Topics: Cardiovascular Diseases; Citalopram; Death, Sudden, Cardiac; Drug Therapy, Combination; Female; Foll | 2019 |
Electrocardiogram Monitoring After the Food and Drug Administration Warnings for Citalopram: Unheeded Alerts?
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Citalopram; Drug Monitoring; Electrocardiography; | 2018 |
The cardiovascular safety profile of escitalopram.
Topics: Adult; Aging; Blood Pressure; Cardiovascular Diseases; Citalopram; Electrocardiography; Female; Hear | 2013 |
Clinical toxicology of citalopram after acute intoxication with the sole drug or in combination with other drugs: overview of 26 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Central Nervous System Diseases | 2008 |
Clarification of the Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment (REMIT) trial protocol.
Topics: Cardiovascular Diseases; Citalopram; Depressive Disorder; Humans; Selective Serotonin Reuptake Inhib | 2012 |
Comparative animal studies on cardiovascular toxicity of tri- and tetracyclic antidepressants and citalopram; relation to drug plasma levels.
Topics: Anesthesia; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cardiac Output; Cardio | 1984 |
Antidepressant drugs and heart electrical field.
Topics: Adult; Amitriptyline; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cardiovascular Diseas | 1998 |